Explore jobs
Find specific jobs
Explore careers
Explore professions
Best companies
Explore companies
ALZA Corporation history
ALZA Corporation company history timeline
Doctor Zaffaroni, 64 years old, a biochemist who started the company with his own funds in 1968, will remain as co-chairman.
Although the company was small, it pursued its mission diligently, filing a patent application for a transdermal system invented by Zaffaroni in 1969.
1974: Ocusert Pilo-20/40 becomes the first ALZA product to gain FDA approval.
1977: Ciba-Geigy gains controlling interest in ALZA.
1981: FDA approves ALZA's first transdermal product, the Transderm Scop.
In 1982, after a buyout, Alza became an independent company once again.
Doctor Zaffaroni had invested more than $1 million and the company did not turn a profit until 1983, 15 years after it was founded.
Transderm-Nitro became the first ALZA product to hit $100 million in combined licensee sales, and company revenues had reached $71 million by 1987, when Gerstel was named CEO and cochairman.
In 1989, the FDA approved ALZA's Procardia XL tablets, and Pfizer Inc. began to market the drug for treatment of angina and hypertension under a royalty license from ALZA.
Revenues for that year reached $109.4 million, up from $92.7 million in 1989.
By 1990, ALZA had about 40 products in development and 650 employees, more than half of whom comprised the research and development team.
1990: FDA approves Duragesic transdermal system for the management of cancer pain.
In 1991, to consolidate its stake in electrotransport systems, the company announced that it would acquire Bio-Electro Systems as well as Medtronic Inc.'s electrotransport business unit.
ALZA stock was trading at $80 a share in late 1991, double the price it garnered the year before.
1991: FDA approves the Nicoderm nicotine patch.
Elan's American marketing partner, American Cyanamid, joined in the lawsuit, but by mid-1992 the suit was withdrawn and the parties reached an out-of-court settlement with no financial impact to those involved.
ALZA recovered its stride, and the company's stock began trading on the New York Stock Exchange in the summer of 1992.
The company celebrated its 25th anniversary in 1993.
1993: Company forms Therapeutic Discovery Corporation to do research on new products; Doctor Ernest Mario is named CEO of ALZA.
1994Established The history of the company dates back to the 29th of November 1994, when Mr.
1994: Testoderm hormone replacement therapy system is introduced.
1995 - 96Alzasoft for Students Alzasoft became a popular choice for students, with customers being introduced to the company via advertising campaigns targeting student residences and educational establishments throughout the country.
Hired to lead the team as CEO and cochairman was Doctor Ernest Mario, a former chief executive of Glaxo Holdings P.L.C. Mario became sole chairman at the end of 1997 upon Zaffaroni's retirement.
In June 1999 ALZA agreed to be acquired by Abbott Laboratories for $7.3 billion in stock, with ALZA slated to become a division of Abbott.
Net income for 1999 was $91 million.
In March 2000 the FDA approved Viadur for the palliative treatment of advanced prostate cancer.
Nearing FDA approval in mid-2000 was Concerta, a once-daily treatment of attention deficit/hyperactivity disorder that used the OROS technology.
Alza has over 2000 employees
The upgraded version of the eShop was upended by the devastating floods of August 2002.
In May 2008, the company completely rebranded to Alza.cz in the Czech Republic, and Alza.sk in Slovakia, and a new store was opened in Brno.
It is now a purely Czech joint stock company, with its tax domicile also in the Czech Republic. It became a market leader in 2008 and has received several prestigious awards over the years in recognition of the quality service it offers to millions of customers.
In Autumn 2010, the company significantly expanded its warehouse space by adding a new logistics warehouse in Horní Počernice.
Won of Shop of the Year 2012, "Crystal Zoom" 2012, and Mastercard Retailer of the year 2012 awards
Won the MasterCard Internet Marketer of the year 2013 in the Czech Republic, and victory in the first edition of the same competition in Slovakia
Won the Shop of the Year 2014 Competition – Quality Award
Third edition of Alza Awards was hosted, with SONY PlayStation VR winning Product of the Year 2016
In 2017, Alza served over 2.9 million unique customers
2019 A new Call Centre opened in Třinec, Czech Republic.
Rate how well ALZA Corporation lives up to its initial vision.
ALZA Corporation jobs
Do you work at ALZA Corporation?
Is ALZA Corporation's vision a big part of strategic planning?
ALZA Corporation competitors
| Company name | Founded date | Revenue | Employee size | Job openings |
|---|---|---|---|---|
| DSM Pharmaceuticals Inc | 1993 | $850.0M | 1,200 | - |
| Catalent Pharma Solutions | 2007 | $4.4B | 14,000 | 356 |
| Coldstream Labs | 2007 | $3.5M | 50 | - |
| Sigma-Aldrich | 1951 | $2.8B | 9,600 | - |
| Lantheus | 1956 | $1.5B | 612 | 43 |
| G&W Laboratories | 1919 | $527.2M | 300 | - |
| Pacira BioSciences | 2006 | $675.0M | 750 | 16 |
| West-Ward Pharmaceuticals | 1946 | $150.0M | 249 | 55 |
| Actavis Laboratories FL, Inc. | 2002 | $162.9M | 900 | - |
| Ivax Research | 1987 | $2.2B | 10,100 | - |
ALZA Corporation history FAQs
Zippia gives an in-depth look into the details of ALZA Corporation, including salaries, political affiliations, employee data, and more, in order to inform job seekers about ALZA Corporation. The employee data is based on information from people who have self-reported their past or current employments at ALZA Corporation. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by ALZA Corporation. The data presented on this page does not represent the view of ALZA Corporation and its employees or that of Zippia.
ALZA Corporation may also be known as or be related to ALZA Corporation and Alza.